Últimas noticias sobre Intuitive Surgical (NASDAQ:ISRG) Bolsa

INTUITIVE SURGICAL INC

Intuitive Surgical

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.

Nvidia,Chip,On,Illuminated,Circuit,Board,ñ,Glowing,Green,Logo

Equities

News

Markets

ABBNY

ISRG

NVDA

Nvidia ha cimentado un dominio en IA difícil de igualar, aunque AMD logra reconocimiento en robótica y sistemas embebidos.

Nvidia construye ventaja casi imbatible en IA, pero AMD destaca en sectores clave

What Wedbush’s Dan Ives Said

DASH

PLTR

Palantir se une al S&amp;P 100 tras subir un 60% y consolidarse como líder en la IA. ¿Seguirá su ascenso o enfrentará correcciones?

Palantir (PLTR) al S&amp;P 100 y subiendo: proyección de los analistas sobre su precio futuro

Analyst Color

Market Summary

Futures

Pre-Market Outlook

Analyst Ratings

ETFs

ALUR

STBX

Los futuros de acciones cayeron tras la decisión del BOJ de subir tasas al 0,5%. Analiza el impacto en los mercados.

Futuros de EE.UU. caen tras aumento de tasas del Banco de Japón: Análisis y previsiones clave

Intuitive Surgical Inc

In a recent report, Cathie Wood&#8216;s ARK Invest has said that the widespread adoption of humanoid robots could potentially unlock a massive $250 billion in untapped gross domestic product (GDP).
What Happened: The article <a href="https://www.ark-funds.com/articles/etf/humanoid-robotics">from</a> Ark Invest delves into the potential economic impact of humanoid robots. It suggests that the adoption of humanoid robots could lead to a significant boost in productivity, potentially unlocking $250 billion in untapped GDP.
The report highlights the key players driving the AI revolution, including Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>).
The article points out that the U.S. is currently facing a labor shortage, and the adoption of humanoid robots could help alleviate this issue. It highlights the potential cost savings associated with the adoption of humanoid robots over human labor.
Wood&#8217;s report also identifies the key players driving the AI revolution. It singles out Tesla, Nvidia, and AMD as the companies at the forefront of this transformative technology.
See Also: <a href="https://benzinga.com/markets/tech/25/06/46046476/barack-obama-warns-ai-revolution-is-not-hype-says-youre-going-to-start-seeing-shifts">Barack Obama Warns AI Revolution Is &#8216;Not Hype,&#8217; Says &#8216;You&#8217;re Going To Start Seeing Shifts&#8230;&#8217;</a>
Why It Matters: In a recent interview, Nvidia CEO Jensen Huang suggested that Tesla&#8217;s humanoid robot, Optimus, could be the first to achieve mass adoption and trigger a multi-trillion-dollar industry. This forecast is in line with a UBS report, which predicts that the number of humanoid robots in operation will reach 2 million by 2035 and a staggering 300 million by 2050.
Tesla CEO Elon Musk has also highlighted the cost-effectiveness of humanoid robots, stating that the cost of making an Optimus is half that of manufacturing a Tesla EV despite the complexity of the humanoid robot.
Robotics company Figure AI recently secured $675 million in funding and is in talks with UPS to integrate its humanoid robots into the global shipping giant&#8217;s logistics infrastructure. This surge in investment is expected to drive the global market for humanoid robots, with the UBS report predicting a significant increase in their numbers by 2050.
Read Next:
<ul class="wp-block-list">
<li><a href="https://benzinga.com/markets/tech/25/06/46055372/new-crypto-fund-targets-early-builders-is-this-where-the-next-blockchain-unicorn-starts">New Crypto Fund Targets Early Builders: Is This Where The Next Blockchain Unicorn Starts? &#8211; Benzinga</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

AMZN

TSLA

Cathie Wood's ARK Invest Predicts $250 Billion GDP Boost From Humanoid Robot Adoption: TSLA, NVDA, AMD To Drive AI Revolution

Editor&#8217;s note: This article was updated to correct the details of the ETF.
<a href="https://www.benzinga.com/etfs">AI-themed ETFs</a> have proliferated in recent years, and many of them loaded with so-called &#8220;<a href="https://www.benzinga.com/topic/magnificent-seven">magnificent seven&#8221; tech giants</a>. 
However, not all are designed to endure the next innovation cycle. As the discussion moves from &#8220;what&#8217;s hot&#8221; to &#8220;what stands the test of time,&#8221; a new generation of ETFs is on the rise—those that adapt.
One such fund is the Dan IVES Wedbush AI Revolution ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVES#NYSE">IVES</a>). The <a href="https://www.benzinga.com/etfs/new-etfs/25/06/45774136/wedbush-launches-ai-revolution-etf-backed-by-dan-ives-proprietary-tech-picks">ETF, launched on June 4</a>, managed to <a href="https://www.globenewswire.com/news-release/2025/06/13/3099005/0/en/Dan-IVES-AI-Revolution-ETF-Surpasses-100-Million-AUM-Within-First-Trading-Week-of-Wedbush-Fund-Advisers-Inaugural-Offering.html">pull</a> in $100 million in only five trading days.
IVES &#8220;is built to be disciplined and transparent,&#8221; Wedbush Fund Advisers CIO Cullen Rogers tells Benzinga. &#8220;We don't react to short-term performance or headlines.&#8221;
IVES rebalances quarterly and aligns with revisions to the AI30 model developed by Wedbush&#8217;s Dan Ives, who created the methodology. This frequency steers clear of performance-chasing whiplash from more active managers, while retaining thematic relevance.
The fund &#8220;follows a clear set of rules and reflects the ongoing evolution of Dan's AI30 framework. That combination of research-driven insight alongside a passive index structure gives us the ability to stay focused on the long term,&#8221; Rogers added.
Also Read: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/45978750/why-smart-money-is-spreading-out-etf-flows-signal-surge-in-portfolio-diversification">Why Smart Money Is Spreading Out: ETF Flows Signal Surge In Portfolio Diversification</a>
<h2 class="wp-block-heading">The Case Against Static AI ETFs</h2>
Global X Robotics &amp; Artificial Intelligence ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOTZ#NASDAQ">BOTZ</a>) and ROBO Global Robotics and Automation ETF (ROBO) both have portfolios that lean towards robotics, semiconductors, and infrastructure-heavy hardware. 
BOTZ, for example, has Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), and Keyence (OTCPK: KYCCF) as its leading holdings. 
ROBO has a strong tilt into industrials and health tech.
But these ETFs tend to be afflicted by static index approaches that fail to adjust rapidly to new AI subsectors like inference engines, generative software, or quantum compute.
<h2 class="wp-block-heading">Inside IVES: A Living Portfolio For A Moving Target</h2>
IVES employs a modified market-cap weighting strategy to keep its biggest bets in check. Yes, it includes the likes of Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Nvidia, and Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>). However, it also leaves room for lesser-known high-conviction picks.
&#8220;We intentionally moved away from traditional straight-line market-cap weighting to avoid exactly that issue (overconcentration and valuation risk tied to the magnificent seven stocks). The modified market-cap weighting approach we use helps large-cap leaders hold influence, but it also prevents them from overwhelming the rest of the portfolio. At the same time, it gives room for smaller, high-conviction names to matter,&#8221; said Rogers.
IVES takes a tight, research-driven approach, Rogers explains. 
"This isn't about market timing — it's about giving investors access to the companies actually building and monetizing the AI revolution, in a format that's disciplined and transparent," he adds.
<h2 class="wp-block-heading">What Happens In A Downturn?</h2>
With valuations across the tech sector under renewed scrutiny, some wonder if AI ETFs are a bubble waiting to pop. Rogers isn't fazed. "Short-term market swings are part of investing, but IVES is built for the long run. What sets the fund apart is its ability to evolve with the AI ecosystem. Not just where it is today, but where it&#8217;s going. That's the advantage of anchoring the portfolio to Dan's ongoing research. As AI matures and new players, platforms, or verticals emerge, the index can adapt," he said.
&#8220;If the center of gravity in AI shifts from semis to inference, or from traditional compute to quantum, Dan's research is positioned to catch that. And our structure is designed to follow it. So even through a downturn, we're confident the fund will stay aligned with the most important parts of the AI value chain as they evolve,&#8221; Rogers emphasized.
Contrast that with holdings such as BOTZ, where old-school industrials and automation stocks constitute a huge percentage of the assets. They&#8217;re exposed to AI, perhaps, but sometimes indirectly and without the agility to change direction quickly.
<h2 class="wp-block-heading">Investor Takeaway: Adaptive &gt; Aggressive</h2>
For individual investors, the message is straightforward: not to conflate AI exposure with AI relevance. BOTZ funds might have expansive baskets, but that expansiveness tends to be at the expense of thematic integrity and forward-looking design. ROBO still stands for its robotics theme and first-mover appeal, but perhaps it will not be the final say on AI innovation as it extends into software.
IVES, on the other hand, presents a more streamlined style that balances conviction with agility. It&#8217;s not attempting to be everywhere, it&#8217;s trying to be where the AI narrative is really headed.
If the previous cycle of AIs revolved around who could train the largest model, perhaps the next will be a question of who can best monetize it. In that game, flexibility, not merely exposure, may be the ultimate advantage.
As Rogers summarizes: &#8220;IVES isn't a static snapshot, it's a living framework.&#8221;
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/06/45975763/risk-on-revival-growth-themed-etfs-hit-52-week-highs-as-market-calms-down">Risk-On Revival: Growth-Themed ETFs Hit 52-Week Highs As Market Calms Down</a></li>
</ul>
Image: Shutterstock

Specialty ETFs

BOTZ

IVES

KYCCF

MSFT

Beyond Magnificent 7: Can Thematic ETFs Like IVES Lead The Next Wave Of AI Investing? CIO Cullen Rogers Explains (CORRECTED)

In the current market session, Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) share price is at $512.17, after a 0.53% spike. Moreover, over the past month, the stock fell by 5.07%, but in the past year, went up by 19.38%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1750431648_0.png" alt="Past Year Chart" />

<h3>Intuitive Surgical P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Intuitive Surgical has a better P/E ratio of 74.6 than the aggregate P/E ratio of 51.63 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that Intuitive Surgical Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750431648_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Intuitive Surgical

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 20 years by 17.21% on an annualized basis producing an average annual return of 25.49%. Currently, Intuitive Surgical has a market capitalization of $183.57 billion. 
Buying $1000 In ISRG: If an investor had bought $1000 of ISRG stock 20 years ago, it would be worth $91,843.40 today based on a price of $512.18 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749846617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Intuitive Surgical Stock In The Last 20 Years

Bank of America Securities connected with Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) on reprocessing &#8220;noise&#8221; in the market.
Analyst Travis Steed highlighted that reprocessing is not new to Intuitive, even though it might seem like new news to some investors.
What Happened: For the unversed, in March this year, Restore Robotics received 510(k) <a target="_blank" href="https://www.prnewswire.com/news-releases/restore-robotics-receives-fda-510k-clearance-for-remanufacturing-da-vinci-xi-8mm-monopolar-curved-scissors-302409135.html" rel="noreferrer noopener">clearance</a> from the U.S. Food and Drug Administration (FDA) for remanufacturing Intuitive Surgical&#8217;s Da Vinci Xi Monopolar Scissors as of March 11, 2025, through its subsidiary Iconocare Health.
In a statement, Restore Robotics said it is offering hospitals and surgery centers a cost-effective and sustainable alternative to purchasing instruments from the original manufacturer.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966347/analysts-remain-bullish-on-intuitive-surgical-despite-macro-uncertainty" rel="noreferrer noopener">Analysts Remain Bullish On Intuitive Surgical Despite Macro Uncertainty</a>
In May, Restore Robotics announced that Dr. Eugene Dickens at Hillcrest Medical Center in Tulsa, Oklahoma, conducted the first in-human use of a remanufactured da Vinci&nbsp; Xi robotic instrument on a patient using the newest model robotic surgical system, the da Vinci 5.
In addition, Panama City Surgery Center performed the first in-human use on a da Vinci Xi, which is the workhorse of the da Vinci robotics surgical systems.
Restore Robotics <a target="_blank" href="https://www.prnewswire.com/news-releases/first-in-human-use-of-remanufactured-da-vinci-xi-robotic-instruments-302467048.html" rel="noreferrer noopener">said</a> it is working on getting clearances for other da Vinci robotic instruments.
Why It Matters: Deutsche Bank downgraded Intuitive Surgical from Hold to Sell on Monday, lowering the price forecast from $515 to $440.
BofA analyst Steed noted that some companies have offered services for Intuitive&#8217;s surgical robots and sold remanufactured instruments for years.
Intuitive does not ban third-party remanufactured instruments as long as they have received 510(k) clearance or a similar approval from the FDA.
The company also clarified that it won&#8217;t cancel service contracts, stop doing business, or consider it a contract violation if a U.S. customer uses these FDA-cleared, third-party instruments.
On Friday, BofA maintained the Buy rating with a <a href="https://www.benzinga.com/quote/ISRG/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast of $650</a> and sees continued potential upside to Street estimates.
&#8220;One thing that gives us some comfort that reprocessing will only be a small share of the market over the long term is reprocessing today is only a small low single-digit percent headwind on Medtronic Plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) global surgical business and its isolated mostly in its US vessel sealing and dissection product lines.&#8221;
BofA thinks reprocessing in robotic instruments will only be a small share of customers and tries to innovate accordingly.
On Wednesday, an analyst note by William Blair on this development suggested that hospitals investing millions of dollars in a robotics program will take a pause at operating outside the Intuitive Surgical ecosystem.
The high cost and critical nature of these surgical investments make operating outside of Intuitive&#8217;s established and supported ecosystem a significant risk for healthcare providers, the note added.
Currently, the threat is considered minimal as only one third-party instrument has received FDA clearance, and Intuitive does not offer direct support for such products. While the analyst acknowledged this as a potential long-term risk to watch, the immediate impact is expected to be limited.
Therefore, despite negative headlines that could cause short-term volatility for the premium-valued stock (cited at 57 times 2026 EPS), analyst Brandon Vazquez of William Blair maintains an Outperform rating on the company.
Price Action: ISRG stock is trading lower by 0.72% to $516.70&nbsp;at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45540768/medtronic-beats-q4-forecasts-hikes-dividend-plans-diabetes-spinoff" target="_blank" rel="noreferrer noopener">Medtronic Beats Q4 Forecasts, Hikes Dividend, Plans Diabetes Spinoff</a></li>
</ul>
Image via Shutterstock

Large Cap

Health Care

General

Limited Impact On Intuitive Surgical From Reprocessed Robotic Instruments: Analyst

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) is currently in Phase 17 of its 18-Phase Adhishthana Cycle. While the recent correction may be causing concern among investors, from the perspective of Adhishthana Principles, the pullback appears not only expected but also healthy. Here&#8217;s a breakdown of ISRG's current structure and what lies ahead.
<h3 class="wp-block-heading">ISRG's Alignment with Adhishthana So Far</h3>
Up until Phase 16, ISRG has shown a 70% alignment with the Adhishthana Principles, our proprietary cyclical framework that analyzes stock behavior based on quantitative signals and behavioral archetypes.
One of the clearest and most powerful alignments occurred during Phases 9, 10, and 11, when ISRG completed what is known as the Adhishthana Himalayan Formation.
<h3 class="wp-block-heading">The Adhishthana Himalayan Formation of ISRG</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="549" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11113142/ISRG-Adhishthana-Himalayan-Formation-.png" alt="Fig.1 ISRG Himalayan Formation (Source: Adhishthana.com)" class="wp-image-14253" style="width:772px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11113142/ISRG-Adhishthana-Himalayan-Formation-.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11113142/ISRG-Adhishthana-Himalayan-Formation--300x137.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11113142/ISRG-Adhishthana-Himalayan-Formation--1024x468.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11113142/ISRG-Adhishthana-Himalayan-Formation--768x351.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.1 ISRG Himalayan Formation (Source: Adhishthana.com)</figcaption></figure>
In line with the principles, ISRG began its ascent in Phase 9 and continued to rally until Phase 11. This pattern fits the ideal structure of a Himalayan move. Following this, the stock entered a steep correction, a move known as the Wrath of Ganga — falling nearly 50% and almost touching its Phase 6 Nirvana level at $169.87. This validated the significance of the Nirvana level and confirmed the stock&#8217;s alignment with cyclical expectations.
<h3 class="wp-block-heading">Why ISRG&#8217;s Correction Is Healthy</h3>
ISRG is currently in Phase 17, the penultimate phase in its cycle. According to Adhishthana Principles, Phase 17 is a &#8220;no-action&#8221; phase a time to take no new fresh trades. The success of Phase 18, which is when the stock is expected to attempt Nirvana, or its highest point across the 18-phase cycle, largely depends on the Guna Triads formed in Phases 14, 15, and 16.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="982" height="678" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11113327/ISRG-Stock-Adhishthana-Guna-Triads-.png" alt="Fig.2 ISRG Guna Triads (Source: Adhishthana.com)" class="wp-image-14255" style="width:568px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11113327/ISRG-Stock-Adhishthana-Guna-Triads-.png 982w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11113327/ISRG-Stock-Adhishthana-Guna-Triads--300x207.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11113327/ISRG-Stock-Adhishthana-Guna-Triads--768x530.png 768w" sizes="(max-width: 982px) 100vw, 982px" /><figcaption class="wp-element-caption">Fig.2 ISRG Guna Triads (Source: Adhishthana.com)</figcaption></figure>
In ISRG's case:
<ul class="wp-block-list">
<li>Phases 14 and 15 showed signs of Satoguna — the highest and most constructive of the three gunas. </li>
<li>Phase 16 showed Rajoguna, indicating activity and dual moves.&nbsp;</li>
</ul>
The dominance of Satoguna in the triads suggests a low probability of a severe downtrend during Phase 18's onset. Even if a temporary dip occurs due to Rajoguna, it is likely to be limited and short-lived.
<h3 class="wp-block-heading">ISRG Monthly Chart Alignment and 7-Red Bar Correction</h3>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="422" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11113245/ISRG-C7-Monthly-1024x422.png" alt="" class="wp-image-14254" style="width:602px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11113245/ISRG-C7-Monthly-1024x422.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11113245/ISRG-C7-Monthly-300x124.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11113245/ISRG-C7-Monthly-768x316.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11113245/ISRG-C7-Monthly.png 1190w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Fig.3 ISRG Phase 7 Monthly Chart (Source: Adhishthana.com)</figcaption></figure>
Looking at the monthly chart, ISRG is currently in Phase 7, which corresponds to the Fall of Artah and Artharthi, a phase typically marked by a sequence of red bars or bearish candles. ISRG has already printed two red bars, suggesting that this correction could continue until the 7-red-bar pattern is fulfilled.
Following this, Phase 8 on the monthly chart will begin, a phase associated with the completion of the arc or Cakra, setting the stage for a breakout in Phase 9. A continued decline in the current Phase 7 would help shape a slightly bullish setup going into Phase 8.
<h3 class="wp-block-heading">When to Watch and Accumulate</h3>
The &#8220;death move&#8221; if it occurs, typically happens within the first 26 bars of Phase 18. Until that point, the stock may remain subdued. But both the monthly and weekly chart cycles are pointing toward a bullish alignment beyond that period.
<ul class="wp-block-list">
<li>Phase 18 on the weekly chart begins on 13 October 2025 </li>
<li>This overlaps with a critical window on the monthly chart that continues into early 2026 </li>
</ul>
Given the alignment of both timeframes and the dominance of Satoguna in the triads, the period between 13 October 2025 and 12 April 2026 appears ideal for accumulation.
<h3 class="wp-block-heading">Investor Takeaway</h3>
ISRG's current correction, though uncomfortable, appears healthy and aligned with deeper cyclical structures. It's not a breakdown but a setup. As the stock prepares for a potential supreme move on the monthly chart and a Nirvana attempt on the weekly, investors should observe this phase calmly and plan for strategic entries in the highlighted window.

Technicals

Opinion

Signals

Intuitive Surgical Stock: Why This Correction Is Healthy And What Lies Ahead

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Deutsche Bank analyst Imron Zafar downgraded the rating for Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) from Hold to Sell and lowered the price target from $515 to $440. Intuitive Surgical shares closed at $557.08 on Friday. <a href="https://www.benzinga.com/quote/isrg/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Argus Research analyst Bill Selesky downgraded the rating for Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from Buy to Hold. Tesla shares closed at $295.14 on Friday. <a href="https://www.benzinga.com/quote/tsla/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst James Yaro downgraded the rating for General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) from Buy to Neutral and lowered the price target from $68 to $58. General Mills shares closed at $54.76 on Friday. <a href="https://www.benzinga.com/quote/gis/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Christopher Allen downgraded Interactive Brokers Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) from Buy to Neutral but raised the price target from $205 to $215. Interactive Brokers shares closed at $211.83 on Friday. <a href="https://www.benzinga.com/quote/ibkr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Sidoti &amp; Co. analyst John Franzreb downgraded AZZ Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) from Buy to Neutral and maintained the price target of $101. AZZ shares closed at $94.44 on Friday. <a href="https://www.benzinga.com/quote/azz/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/TSLA/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09114350/image-119-1024x589.png" alt="" class="wp-image-943450" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09114350/image-119-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09114350/image-119-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09114350/image-119-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09114350/image-119.png 1101w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45811726/cramer-says-hes-not-going-to-really-want-to-do-a-lot-of-china-right-now">Cramer Says He&#8217;s &#8216;Not Going To Really Want To Do A Lot Of China Right Now&#8217;</a> </li>
</ul>
Photo via Shutterstock

Downgrades

IBKR

This Tesla Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

WIIM

Intuitive Surgical shares are trading lower after Deutsche Bank downgraded its rating on the stock from Hold to Sell and lowered the price target from $515 to $440.

Deutsche Bank analyst Imron Zafar downgrades Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) from Hold to Sell and lowers the price target from $515 to $440.

Price Target

Deutsche Bank Downgrades Intuitive Surgical to Sell, Lowers Price Target to $440

Deep-pocketed investors have adopted a bullish approach towards Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ISRG usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Intuitive Surgical. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 25% bearish. Among these notable options, 2 are puts, totaling $132,426, and 10 are calls, amounting to $704,446.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $290.0 and $780.0 for Intuitive Surgical, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Intuitive Surgical's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Intuitive Surgical's substantial trades, within a strike price spectrum from $290.0 to $780.0 over the preceding 30 days.
<h3>Intuitive Surgical 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749060084_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$280.1</td>
<td>$280.0</td>
<td>$280.0</td>
<td>$290.00</td>
<td>$280.0K</td>
<td align="right">28</td>
<td align="right">10</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/03/25</td>
<td>$20.1</td>
<td>$18.4</td>
<td>$19.75</td>
<td>$555.00</td>
<td>$98.7K</td>
<td align="right">4</td>
<td align="right">50</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$49.4</td>
<td>$49.3</td>
<td>$49.3</td>
<td>$560.00</td>
<td>$98.7K</td>
<td align="right">135</td>
<td align="right">21</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$115.2</td>
<td>$112.4</td>
<td>$115.2</td>
<td>$500.00</td>
<td>$57.6K</td>
<td align="right">156</td>
<td align="right">5</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$36.0</td>
<td>$35.1</td>
<td>$36.0</td>
<td>$540.00</td>
<td>$50.4K</td>
<td align="right">98</td>
<td align="right">16</td>
</tr>
</tbody>
</table>

<h3>About Intuitive Surgical</h3>
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.
In light of the recent options history for Intuitive Surgical, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Intuitive Surgical Standing Right Now?</h3>
<ul>
<li>With a volume of 509,158, the price of ISRG is up 1.03% at $557.56. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 43 days.</li>
</ul>
<h3>What The Experts Say On Intuitive Surgical</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $650.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Intuitive Surgical with a target price of $650. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intuitive Surgical with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

What the Options Market Tells Us About Intuitive Surgical

Watching Intuitive Surgical; Hearing Investor Business Daily's SwingTrader Picks Stock

Chipmaker Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) may have carved out a lead for itself in AI that is nearly impossible to dislodge, according to a former Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) engineer, who believes that the latter might still have an upper hand across a few niche areas.
What Happened: On Monday, AlphaSense, an expert network that connects investors with subject-matter experts, shared the call transcript of one such conversation between an analyst and an ex-AMD engineer.
The expert in the call outlined the reasons Nvidia&#8217;s dominance in AI seems unassailable, and it has to do with what&#8217;s currently being taught to students at the university level.
According to the expert, universities are training students on Nvidia's software, making its tools and libraries the default. See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45739051/tsmc-ceo-admits-trump-tariffs-have-some-impact-on-chipmaker-but-demand-consistently-outpacing-supply-thanks-to-ai">TSMC CEO Admits Trump Tariffs Have &#8216;Some Impact&#8217; On Chipmaker But Demand &#8216;Consistently Outpacing&#8217; Supply Thanks To AI</a>
They credit this to the company&#8217;s early and aggressive investment in AI tooling, leaving it with such a deeply entrenched software dominance that newer entrants and even established rivals like AMD might struggle to match.
&#8220;Nvidia was investing extremely heav[ily]… 20 years ago, on AI and large language models,&#8221; the expert said. &#8220;You could almost call it throwing away money at the time.&#8221;
This strategy, they note, has since paid off, with Nvidia now having what they call an &#8220;unassailable tool flow and library for all things AI.&#8221;
Yet, they highlighted certain meaningful strengths of AMD, particularly in the realm of robotics. Unlike Nvidia's top-down strategy focused on high-level processing, AMD has built credibility in low-level motor control and embedded systems, they say. 
In fact, companies like Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) and ABB Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ABBNY#OTC">ABBNY</a>) have both publicly endorsed AMD for its contributions to real-time robotics tasks. 
While Nvidia dominates in vision AI and large-scale inference, areas crucial to humanoid robotics and LLM applications, AMD's bottom-up capabilities position it well in industrial and healthcare robotics, where power efficiency and real-time control matter more than raw GPU horsepower, according to the expert.
<figure class="wp-block-embed aligncenter is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Former <a href="https://twitter.com/search?q=%24AMD&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$AMD</a> employee shares his view on the positioning of <a href="https://twitter.com/search?q=%24AMD&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$AMD</a> and <a href="https://twitter.com/search?q=%24NVDA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$NVDA</a> in the robotics industry: &#8211; According to the expert, AMD is heavily involved in many subsystems that make up robotics systems. <a href="https://twitter.com/search?q=%24AMD&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$AMD</a> grew from the bottom up, in contrast to <a href="https://twitter.com/search?q=%24NVDA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$NVDA</a>, which, according to the… <a href="https://t.co/iJE0GAq8HC">pic.twitter.com/iJE0GAq8HC</a>
&mdash; AlphaSense (@AlphaSenseInc) <a href="https://twitter.com/AlphaSenseInc/status/1929561262712832286?ref_src=twsrc%5Etfw">June 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: According to recent reports, AMD is <a href="https://www.benzinga.com/25/05/45550527/amd-takes-on-nvidia-stock-with-direct-shot-at-gpus-reviewer-says-rx-9060-could-hit-the-bullseye">catching up with Nvidia</a> in the GPU race rather quickly, with new products that offer considerably more bang for the buck, or as one reviewer called it, &#8220;15% better gaming performance per dollar,&#8221; relative to Nvidia&#8217;s 5060 Ti.
Tech giants, such as Elon Musk&#8217;s xAI, too, have committed to buying many GPUs from Nvidia in the months to come, along with &#8220;some from AMD.&#8221;
Price Action: AMD shares were up 3.52% on Monday, trading at $114.63, while Nvidia shares traded at $137.38, up 1.37%. Both stocks are flat after hours, up 0.11% and 0.01%, respectively.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="138" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03022201/Screenshot-2025-06-03-at-11.51.47-AM-1024x138.png" alt="" class="wp-image-936043" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03022201/Screenshot-2025-06-03-at-11.51.47-AM-1024x138.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03022201/Screenshot-2025-06-03-at-11.51.47-AM-300x41.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03022201/Screenshot-2025-06-03-at-11.51.47-AM-768x104.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03022201/Screenshot-2025-06-03-at-11.51.47-AM-1536x207.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03022201/Screenshot-2025-06-03-at-11.51.47-AM.png 1614w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Nvidia ranks well on Momentum and Growth according to Benzinga&#8217;s Edge Stock Rankings, while having a favorable price trend in the short, medium, and long term. How does it compare with Nvidia? Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a> to find out. 
Photo Courtesy: Hepha1st0s On Shutterstock.com
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/social-media/25/06/45738963/elon-musks-xai-targets-113-billion-valuation-with-300-million-share-sale-report">Elon Musk&#8217;s xAI Targets $113 Billion Valuation With $300 Million Share Sale: Report</a></li>
</ul>

Nvidia's 20-Year AI Bet Creates 'Unassailable' Moat, Warns Ex-AMD Engineer

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 5 years by 9.52% on an annualized basis producing an average annual return of 23.37%. Currently, Intuitive Surgical has a market capitalization of $197.97 billion. 
Buying $100 In ISRG: If an investor had bought $100 of ISRG stock 5 years ago, it would be worth $288.38 today based on a price of $552.34 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748647811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Intuitive Surgical 5 Years Ago Would Be Worth This Much Today

In the current session, the stock is trading at $555.50, after a 0.56% spike. Over the past month, Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) stock increased by 7.71%, and in the past year, by 38.53%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1748541663_0.png" alt="Past Year Chart" />

<h3>Intuitive Surgical P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Intuitive Surgical has a better P/E ratio of 80.88 than the aggregate P/E ratio of 53.03 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that Intuitive Surgical Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748541663_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 20 years by 17.64% on an annualized basis producing an average annual return of 25.97%. Currently, Intuitive Surgical has a market capitalization of $199.56 billion. 
Buying $1000 In ISRG: If an investor had bought $1000 of ISRG stock 20 years ago, it would be worth $100,948.13 today based on a price of $556.78 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747845013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Intuitive Surgical 20 Years Ago Would Be Worth This Much Today

Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has announced a major leadership transition, appointing Dave Rosa as the company&#8217;s next <a href="https://www.benzinga.com/pressreleases/25/05/g45436448/intuitive-announces-ceo-transition-effective-july-1-2025">chief executive officer, effective July 1, 2025</a>.
Rosa, who currently serves as president, will succeed long-serving CEO Gary Guthart, who will become the executive chair of the board.
The move is part of a broader succession strategy as the robotic-assisted surgery pioneer celebrates its 30th anniversary.
As part of the transition, Craig Barratt, the current board chair, will take on the role of lead independent director.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45438765/why-pfizer-is-poised-for-a-strong-comeback-my-top-pick-for-2025" target="_blank" rel="noreferrer noopener">Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025</a>
Guthart, who has led the company for 15 years, will stay on in a senior advisory capacity to support a seamless transition.
Rosa, who joined Intuitive nearly 30 years ago as its ninth employee, has served in multiple roles across engineering, product development, marketing, and commercial operations.
The company recently revealed that the FDA has recently cleared Intuitive&#8217;s da Vinci SP system for transanal local excision/resection, a minimally invasive surgery <a href="https://www.benzinga.com/pressreleases/25/05/g45135080/intuitive-announces-fda-clearance-of-da-vinci-single-port-for-transanal-local-excisionresection" target="_blank" rel="noreferrer noopener">done without abdominal cuts</a>.
This expands the system&#8217;s use in colorectal procedures through natural orifices. It builds on earlier FDA approvals from November 2024 for several transabdominal colorectal surgeries.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, ISRG stock has gained over 39% in the past year.
Investors can gain exposure to the stock via&nbsp;Spinnaker ETF Series Langar Global HealthTech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGHT#NYSE">LGHT</a>) and&nbsp;iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHI#NYSE">IHI</a>).
Price Action: ISRG shares are trading lower by 1.69% to $556.38 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45439079/powell-signals-fed-may-shift-its-inflation-strategy-after-5-year-economic-shake-up" target="_blank" rel="noreferrer noopener">Powell Signals Fed May Shift Inflation Strategy After 5 Years Of Economic Upheaval</a></li>
</ul>
Image via Shutterstock

Management

Movers

iShares Dow Jones US Medical Devices Index Fund

LGHT

What's Going On With Intuitive Surgical Stock On Thursday?

Intuitive Surgical Current CEO Gary Guthart To Become Executive Chair Of The Board

President Dave Rosa promoted to CEO Current CEO Gary Guthart to become executive chair of Intuitive's board Current Board Chair Craig Barratt to become lead independent director
SUNNYVALE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the promotion of President Dave Rosa to chief executive officer, effective July 1, 2025. At that time, current CEO Gary Guthart will become the executive chair of Intuitive's board of directors, and current Board Chair Craig Barratt will become lead independent director. Guthart will work closely with Rosa to support a smooth transition and will remain with Intuitive in a senior advisory capacity.

Intuitive Promotes President Dave Rosa To CEO, Effective July 1, 2025

Live On CNBC, Stephanie Link Announces Sold Eli Lilly and Co; Announces Bought More Intuitive Surgical

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 10 years by 15.11% on an annualized basis producing an average annual return of 25.4%. Currently, Intuitive Surgical has a market capitalization of $189.54 billion. 
Buying $100 In ISRG: If an investor had bought $100 of ISRG stock 10 years ago, it would be worth $958.86 today based on a price of $528.83 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746540023_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Intuitive Surgical Stock In The Last 10 Years

Press Releases

Astera Labs Appoints Dr. Craig Barratt to Board of Directors

Mutual Funds

DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

Peer-Reviewed Studies on Intuitive's Force Feedback Technology Demonstrate its Potential to Reduce Force on Tissue and Enhance Surgeon Performance

Small Cap

AI-Powered Service Robots Redefine Hospitality as Industry Innovators Lead the Charge

U.S. FDA clears first stapler designed for single-port robotic surgery

New Research Explores Access to Minimally Invasive Care and the Impact of Robotic-Assisted Surgery

Earnings

Intuitive Announces First Quarter Earnings

Intuitive Announces FDA Clearance of da Vinci Single Port for Transanal Local  Excision/Resection

Intuitive Announces CEO Transition Effective July 1, 2025

30 years of Innovation and Impact: Dan Larson's Inspiring Story

ALAB

AMBC

BBWI

CLSK

FLGT

FRPT

GDOT

GPRE

HAIN

HIMS

KTOS

MATV

NEOG

NGTF

SATS

SERV

SPGI

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

TransMedics Group

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Deutsche Bank

Citigroup

Barclays

RBC Capital

Truist Securities

Untitled design - 2024-12-10T185819.364

Movers & Shakers

MBOT

Palm-Sized Innovation: How Microbot Medical Is Helping Redefine Surgical Robotics

Comments

Intuitive Surgical

Noticias

Últimas noticias sobre Intuitive Surgical (NASDAQ:ISRG) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL